POM

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement. As these capabilities reinforce one another with minimal manual int

6-K - POMDOCTOR Ltd (0001877971) (Filer)

Anchoring Established Healthcare Operations to Technology-Enabled Growth OpportunitiesGUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its four-tier diversified revenue structure, which is designed to build on the Company's established healthcare operations while developing scalable, technology-enabled services. The Company's four-tier revenue structure consists of B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, along wit

S-8 - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the matter has been closed. As previously disclosed, on January 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid pri

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade, officially positioning the Company as a foundational infrastructure provider for predictive healthcare data and services. The strategic upgrade reflects the Company's continued evolution from a traditional online healthcare platform toward an artificial intelligence ("AI")-enabled healthcare infrastructure provider. By integrating wearable technologies, AI, physician services, real-world healthcare data, and healthcare payment networks, POM aims to develop an intelligent healthcare ecosys

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, June 17, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced that, as previously announced on May 28, 2026, the ratio change of its American depositary shares (the "ADSs") to Class A ordinary shares from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares (the "ADS Ratio Change") will become effective on June 22, 2026, U.S. Eastern Time (the "Effective Date"). For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen re

F-6 POS - POMDOCTOR Ltd (0001877971) (Subject)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, May 28, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its Class A ordinary shares (the "ADS Ratio Change"), from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares. For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with th

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy. Both our net revenues and gross profit recorded solid year-over-year increases, by 16.7% and 9.6% respectively, primarily driven by the strong growth of our Internet hospital business, particularly online pharmacy sales as we deepened collaborat

20-F - POMDOCTOR Ltd (0001877971) (Filer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

NT 20-F - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)